

Tenth EUCAST Steering Committee Meeting

Summary of minutes of meeting in Copenhagen, Denmark, 31 March – 1 April 2005

Attending

Dr Derek F.J. Brown	DB	Scientific Secretary	United Kingdom
Dr Gunnar Kahlmeter	GK	Chairperson	Sweden
Prof Alasdair P. MacGowan	AM	BSAC	United Kingdom
Dr Johan W. Mouton	JM	CRG	The Netherlands
Dr Ingrid Nilsson-Ehle	IN-E	SRGA	Sweden
Prof Arne Rodloff	AR	DIN	Germany
Prof Claude-James Soussy	C-JS	SFM	France
Dr Martin Steinbakk	MS	NWGA	Norway
Dr Francisco Soriano	FS	EUCAST	Spain
Dr Olga Stetsiouk	OS	EUCAST	Russia

Apologies

Dr Anders Österlund	AO	SRGA	Sweden
Dr Fred Goldstein	FG	SFM	France

Attending for item 16

Dr Bill Craig	BC	CLSI	USA
Dr Mike Dudley	MD	CLSI	USA
Dr Ron Jones	RJ	CLSI	USA

1	Chairman's welcome IN-E represented SRGA in place of AÖ and C-JS represented SFM in place of FG. BC, MD and RJ joined the meeting for the afternoon of 1 April for joint discussions with the CLSI.
2	Minutes of meeting of 22-23 November 2004 With a few typographical corrections the minutes were accepted as a correct record.
3	Matters arising from minutes of 22-23 November 2005 Updating of Intracellular Pathogens and Mycobacteria documents are being pursued. Antifungal subcommittee would be meeting at ECCMID 2005 and would be encouraged to proceed with setting breakpoints for antifungal agents as agreed in the DG-Sanco grant. Aminoglycoside breakpoints tables have been updated and rationale documents modified to reflect changes agreed with CA-SFM. All breakpoint tables now have issue dates. A draft daptomycin rationale document has been produced. Further aztreonam MIC data for <i>Pseudomonas</i> is required. Footnote added to cefuroxime in breakpoint table regarding absence of clinical response for strains of <i>Salmonella</i> and <i>Shigella</i> appearing susceptible. MIC data for cefepime and <i>N. gonorrhoeae</i> are being sought. Cefpirome removed and ceftazidime added to draft breakpoint tables. Tables of tentative cephalosporin and carbapenem breakpoints distributed to Steering Committee for consultation with national committees. Problems with Iso-Sensitest agar had been discussed with Oxoid who have agreed to co-operate

in further investigation of the problem.

Definition of the intermediate category in the ISO method to be added to agenda of next meeting.

An updated version of the EUCAST powerpoint presentation is on the EUCAST website.

4 CLSI (NCCLS) meeting Tampa

There were discussions between CLSI and FDA regarding the mechanism to change breakpoints. The voting members agreed to review breakpoints for cephalosporins and Enterobacteriaceae in collaboration with EUCAST.

5 Tigecycline breakpoints

The process of setting breakpoints by EUCAST as part of the EMEA protocol for registration of new drugs is continuing.

6 Daptomycin breakpoints

The process of setting breakpoints by EUCAST as part of the EMEA protocol for registration of new drugs is continuing.

7 Carbapenems

Discussions on proposed harmonised breakpoints and draft rationale documents continued following comments from national committees. Adjustments made will be discussed further at national committees before the next meeting of EUCAST.

8 Joint meeting with EARSS, November 24-26 2005

A EUCAST workshop for the General Committee members combined with an EARSS managers meeting will be led by EUCAST for half the meeting and by EARSS for the rest. Items for the agenda are invited.

9 ECCMID Copenhagen April 2-5 2005

A EUCAST workshop for members of national committees, a EUCAST symposium on resistance to cephalosporins in Enterobacteriaceae, and the EUCAST General Committee Meeting have been organised.

10 Requests for EUCAST presentations at scientific meetings

EUCAST members are happy to speak about EUCAST at meetings but EUCAST cannot fund expenses and those making the invitation should cover all costs.

11 EMEA

The EMEA SOP for setting breakpoints for new agents is now official.

12 Collaboration with other groups

The European veterinary group (ARBAO), the European group on gonococci (ESSTI) and the European meningococcal group are all collaborating in the development of harmonised breakpoints.

13 Glycopeptide breakpoints for staphylococci

Agreed that no changes would be made to current breakpoints but would be discussed again.

14 Moxifloxacin breakpoints for staphylococci

Tentative breakpoints for staphylococci and streptococci will be discussed with national committees before the next EUCAST meeting.

15 Rationale documents

Rationale documents supporting EUCAST breakpoints continue to be developed.

16 Cephalosporins

CLSI representatives joined the meeting for discussion of cephalosporin breakpoints.

For each agent the common doses used in Europe and the USA, pharmacodynamic data, MIC distributions, clinical data and draft breakpoints as listed in the draft rationale documents prepared after the last meeting were reviewed. There was extensive discussion and some changes made to draft breakpoints.

The implications of ESBL production for breakpoints and clinical reporting of resistance were a particular area of concern.

National committees will be asked to review revised draft breakpoints for cephalosporins before the next EUCAST meeting.

17 Any other business

Agreed to provide each member with a list of actions ascribed to them in the minutes.

18 Next meetings

12-13 September 2005, Oslo.

21-22 November 2005, Rome. Preceding joint meeting with EARSS.

30-31 January 2006, Munich.

30-31 March 2006, Nice. Preceding ECCMID meeting

12-13 June 2006 (if required)

11-12 September 2006

20-21 November 2006

Ratified summary of minutes of meeting 31 March – 1 April 2005 prepared by DB and GK